Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | CASP7 | P55210 | 2/20 | 0.38 |
| ▸ | CASP6 | P55212 | 2/20 | 0.38 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.38 |
| ▸ | CASP2 | P42575 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | CDC25B | P30305 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 5/20 | 0.37 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | FER | P16591 | 1/20 | 0.37 |
| ▸ | LTK | P29376 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1551145 | 0.77 | GSK3B (0.41) | GSK3BCASP3CASP7CASP6CASP8 | |
| SCHEMBL1450780 | 0.67 | CA12 (0.45) | GSK3BCASP3CASP7CASP6CASP8 | |
| SCHEMBL1438260 | 0.67 | CA12 (0.36) | GSK3BCASP3CASP7CASP6CASP8 | |
| SCHEMBL8123268 | 0.66 | LRRK2 (0.55) | GSK3BCASP3CASP7CASP6CASP8 | |
| SCHEMBL208723 | 0.65 | PDGFRA (0.50) | GSK3BKMT2AMEN1MAOAMAOB | |
| Phthalimide SCHEMBL30125197 | 0.62 | GSK3B (1.00) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL11040503 | 0.62 | GSK3B (1.00) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL29366030 | 0.62 | GSK3B (1.00) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL64 | 0.62 | GSK3B (1.00) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL7771670 | 0.62 | GSK3B (1.00) | GSK3BCASP3CASP7CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024121013-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-06-13 | — | — | WO | claimed |
| EP-3558310-B1 | HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2024-01-17 | — | — | EP | claimed |
| EP-3558307-B1 | 6,6-FUSED HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2023-05-03 | — | — | EP | claimed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | claimed |
| US-11319298-B2 | Heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME CORP. (US) | 2022-05-03 | — | — | US | claimed |
| CN-109689664-B | Tricyclic heteroaryl substituted quinoline and azaquinoline compounds as PAR4 inhibitors | 百时美施贵宝公司 | 2022-04-15 | — | — | CN | claimed |
| US-11230556-B2 | 6,5-fused heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME CORP. (US) | 2022-01-25 | — | — | US | claimed |
| EP-3558306-B1 | 6,5-FUSED HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME (US) | 2021-07-07 | — | — | EP | claimed |
| US-10913733-B2 | Substituted piperidines thiazolyl acetamides as glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2021-02-09 | — | — | US | claimed |
| EP-3389658-B1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2020-11-25 | — | — | EP | claimed |
| EP-1432693-A2 | MCH RECEPTOR ANTAGONISTS | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-06-30 | — | — | EP | claimed |
| EP-1409450-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 2004-04-21 | — | — | EP | claimed |
| US-20030109559-A1 | N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds | PHARMACIA & UPJOHN COMPANY | 2003-06-12 | — | — | US | claimed |
| WO-2003028641-A2 | MCH RECEPTOR ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-04-10 | — | — | WO | claimed |
| WO-2003006423-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | claimed |
| US-6410556-B1 | ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2002-06-25 | — | — | US | claimed |
| EP-1214324-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2002-06-19 | — | — | EP | claimed |
| WO-2001019830-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2001-03-22 | — | — | WO | claimed |
| EP-0048136-B1 | PROCESS FOR PREPARING ALPHA-AROMATIC GROUP SUBSTITUTED ALKANOIC ACIDS OR ESTERS THEREOF | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1986-06-11 | — | — | EP | claimed |
| EP-0048136-A2 | Process for preparing alpha-aromatic group substituted alkanoic acids or esters thereof | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1982-03-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109559-A1 | N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds | BACE1, APP, BACE2 | GSK3B 1168/4885CASP3 211/4885CASP7 369/4885 |
| US-10913733-B2 | Substituted piperidines thiazolyl acetamides as glycosidase inhibitors and uses thereof | OGA, ENGASE, GAA | GSK3B 2319/4885CASP3 4475/4885CASP7 4683/4885 |
| US-11319298-B2 | Heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | CHRM4, CHRM2, CHRM5 | GSK3B 2613/4885CASP3 4503/4885CASP7 4736/4885 |
| US-11230556-B2 | 6,5-fused heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | CHRM5, CHRM4, CHRM2 | GSK3B 3277/4885CASP3 4499/4885CASP7 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.